WuXi Biologics Reports 9.6% Revenue Growth in 2024, Expanding CRDMO Services
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has released its...
Finanical Reports
Fosun Pharma’s 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its 2024...
Burning Rock Reports Q4 Revenue Growth Amid Improved Profitability
Guangzhou-based medical device company Burning Rock (NASDAQ: BNR) has released its Q4 2024 financial results....
Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab
Alphamab Oncology (HKG: 9966) has announced its 2024 financial results, marking a significant milestone with...
Everest Medicines Reports Surge in Revenue, Advances Core Products and R&D Pipeline
China-based Everest Medicines (HKG: 1952) has announced its 2024 financial results, marking a significant milestone...
Simcere Pharmaceutical Group Reports Steady Revenue Amid R&D Investment Shift
China-based Simcere Pharmaceutical Group (HKG: 2096) has released its 2024 financial performance report, recording RMB...
Henlius Biotech Reports 6.1% Revenue Growth with Strong Oncology Product Sales
Shanghai Henlius Biotech Inc. (HKG: 2696) has published its 2024 financial results, recording revenues of...
Sichuan Kelun-Biotech Reports 25.5% Revenue Growth with Key Drug Approvals
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has released its 2024 financial report, recording...
WuXi XDC Reports 90.8% Revenue Surge, Expanding in ADC Market
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA...
Hansoh Pharmaceutical Reports 21% Revenue Growth, Boosted by Innovative Drugs
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) released its 2024 financial report last week,...
Sino Biopharmaceutical’s 2024 Revenue Up 10.2% on Strong Innovative Drug Sales
China-based Sino Biopharmaceutical Ltd (HKG: 1177) released its 2024 financial report, recording revenues of RMB...
HutchMed’s 2024 Financial Report Shows Dip in Revenue Amid Oncology Product Growth
China-based HutchMed (NASDAQ: HCM, HKG: 0013) released its 2024 financial report, revealing a total revenue...
Medbanks Reports 2024 Financial Results Amid Business Reorganization
Sipai Health Technology Co., Ltd (HKG: 0314), known as Medbanks, released its 2024 financial report....
WuXi AppTec Reports Steady Revenue Growth Amid Diversified Business Expansion
China-based Contract Research Organization (CRO) WuXi AppTec (SHA: 603259, HKG: 2359) released its 2024 financial...
FibroGen Reports Decline in Sales, Pushes Ahead with Roxadustat and New Drug Development
US-based biotech FibroGen Inc. (NASDAQ: FGEN) released its Q4 and full-year 2024 financial results, showing...
Grand Pharmaceutical Group Reports Strong 2024 Financials with 12.8% Revenue Growth
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) revealed its 2024 financial performance, recording revenues...
Ping An Healthcare Reports 2024 Financial Turnaround with Growth in Healthcare Services
China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as Ping An...
Legend Biotech Reports Strong Q4 and Full Year 2024 Financial Results
China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q4 and full-year 2024 financial results, highlighting...
MicroPort Scientific Corp. Reports 10% Revenue Growth and 58% Net Loss Decrease in 2024
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) released its 2024 full-year performance estimation....
Merck KGaA Reports 2024 Revenue Growth Despite Challenges in Life Sciences
German major Merck KGaA (ETR: MRK) this week released its 2024 annual report, highlighting a...